Press Releases

Press Releases
Date Title and Summary View
Feb 22, 2017 REVLIMID is the first and only treatment approved for maintenance following auto-HSCT Updated data from two large, randomized, controlled studies demonstrated median progression-free survival (PFS) advantages of 3.8 and 1.9 years, respectively, in favor of patients receiving REVLIMID comp...
Feb 17, 2017 Study met its primary endpoint in reducing annualized relapse rate (ARR) and measured secondary endpoints, compared to interferon (IFN) β-1a (Avonex®) Safety and tolerability consistent with phase II studies Confirmatory phase III RADIANCE trial data expected in Q2 of 201...
Feb 3, 2017 SUMMIT, N.J.--(BUSINESS WIRE)-- Celgene Corporation (NASDAQ:CELG) plans to present at an upcoming investor conference where Celgene management will provide an overview of the Company. The conference will be webcast live and will be available in the Investor Relations section of the Company's website at www.celgen...
Jan 27, 2017 REVLIMID® is the first and only medicine granted positive CHMP opinion for post-Autologous Stem Cell Transplantation (ASCT) maintenance therapy in MM The new indication expands the availability of REVLIMID® across the disease continuum of MM ...
Jan 26, 2017 Net Product Sales $2.98B in Q4:16; Increased 17% Y/Y Net Product Sales $11.18B in 2016; Increased 22% Y/Y 2017 Guidance for Net Product Sales and Diluted EPS SUMMIT, N.J.--(BUSINESS WIRE)-- Celgene Corporation (NASDAQ:CELG) reported opera...
PDF
Add to Briefcase
Jan 26, 2017 Expands pipeline of potential next-generation medicines for the treatment of patients with autoimmune disorders SUMMIT, N.J. & CAMBRIDGE, Mass.--(BUSINESS WIRE)-- Celgene Corporation (NASDAQ: CELG) and Delinia, Inc. ("Delinia"), a privately held biotechnology company developing novel therape...
Jan 9, 2017 Preliminary 2016 Unaudited Financial Results Including Net Product Sales and Diluted EPS Raising 2017 Guidance for Total Revenue and Diluted EPS Reaffirming 2020 Total Revenue and Adjusted Diluted EPS Financial Targets SUMMIT...
PDF
Add to Briefcase
Jan 4, 2017 SUMMIT, N.J.--(BUSINESS WIRE)-- Celgene Corporation (NASDAQ:CELG) will host a conference call and live audio webcast on Thursday, January 26, 2017 at 9 a.m. ET to discuss fourth quarter and full-year 2016 financial and operational results. The webcast can be accessed from the Investor Relations page at www.celgen...
Jan 3, 2017 SUMMIT, N.J.--(BUSINESS WIRE)-- During the 35th Annual J.P. Morgan Healthcare Conference on January 9, 2017 at 10:30 a.m. ET, Celgene Corporation (NASDAQ:CELG) will present a business update on the Company in addition to unaudited 2016 financial results and an updated financial outlook. The presentation and ...
Dec 22, 2016 First-in-class oral treatment for psoriatic arthritis made available via the National Health Service (NHS) STOCKLEY PARK, England--(BUSINESS WIRE)-- Celgene announced today that the National Institute for Health and Care Excellence (NICE) has issued a final appraisal determination (FAD) ...
FirstPrevious
3
... NextLast
Add to Briefcase = add release to Briefcase